- Using PCT patent pending, machine learning analytical platform to develop non-invasive genetic tests
- Received letters of interest from multiple therapeutics companies including Roche and Cassava Sciences
- Finalist for the Xconomy Awards San Diego, selected as one of San Diego Venture group’s "Cool Companies", and graduate of the Creative Destruction Lab program
- CEO has PhD in Population Genetics from University of Chicago and >10 years business experience including a sell-side equity analyst position and senior marketing strategy roles at Illumina
- Strategic advisors include genomics industry executives and scientific advisors from leading academic institutions including Stanford, USC, and WashU
- Total Amount Raised: US $345,000
- Total Round Size: US $2,250,000
- Pre-Seed :
- Minimum Investment: US $5,000 per investor
- : Convertible Note
- US $7,500,000 :
There are >50M living with Alzheimer's disease, with numbers expected to triple in the next 30 years, yet there are zero disease-modifying drugs approved by the FDA that cure, delay the onset, or slow the advance of disease. Drug development in Alzheimer's is notorious for failures, with more than 150 failed trials in the last 20 years. These failures are generally attributed to either the incorrect biology and target of the drug, or because the drug works but has been tested in the wrong patients, at the wrong time, or with the wrong dose. Patient variation can make it difficult to see whether a drug is truly effective or not.
We are addressing the problem of patient variation by developing genetic tests to predict and quantify this variation. With this information, pharma companies are able to better design and analyze clinical trials, which ultimately reduces trial costs, reduces enrollment time, and most importantly to drug developers and to patients, increases the probability that trials and drugs will be successful.
Our approach is aggregating data from thousands of gold standard samples, running that through our proprietary platform, which allows us to develop highly predictive genetic tests to identify brain characteristics that affect disease but can’t easily be seen. Our first two tests have strong predictive performance predicting brain plaques (or amyloid plaques, which are one of the diagnostic criteria of Alzheimer's), and identifying individuals with limited cognitive decline. We have multiple letters of interest from pharma companies, and are in discussion with two companies for pilot studies in Q2-20.
Invite to quarterly company update webinar for investors
All of the above plus a private meeting and dinner with management team
All of the above plus a board observer seat
It is advised that you consult a tax professional to fully understand any potential tax implications of receiving investor perks before making an investment.
Frequently Asked Questions
When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by Vivid Genomics. Once Vivid Genomics accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to Vivid Genomics in exchange for your securities. At that point, you will be a proud owner in Vivid Genomics.
Preferred equity is usually issued to outside investors and carries rights and conditions that are different from that of common stock. For example, preferred equity may include rights that prevent or minimize the effects of dilution or grants special privileges in situations when the company is sold.
A convertible note is a unique form of debt that converts into equity, usually in conjunction with a future financing round. The investor effectively loans money to a startup with the expectation that they will receive equity in the company in the future at a discounted price per share when the company raises its next round of financing.
To learn more about startup investment types check out “How to Choose a Startup Investment” in our academy.
To make an investment, you will need the following information readily available:
- Personal information such as your current address and phone number
- Employment and employer information
- Net worth and income information
- Social Security Number or passport
- ABA bank routing number and checking account number (typically found on a personal check or bank statement)
Because Vivid Genomics is offering its securities under Rule 506(c) of Regulation D, your status as an Accredited Investor will also need to be verified and you will be asked to provide documentation supporting your income, net worth, revenue, or net assets or a letter from a qualified advisor such as a Registered Investment Advisor, Registered Broker Dealer, Lawyer, or CPA.
Until a closing occurs, you may cancel your investment at any time, for any reason. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your portfolio page by clicking your profile icon in the top right corner.
Currently there is no market or liquidity for these securities. Right now Vivid Genomics does not plan to list these securities on a national exchange or another secondary market. At some point Vivid Genomics may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when Vivid Genomics either lists their securities on an exchange, is acquired, or goes bankrupt.
You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement.
This is Vivid Genomics's fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity.
This investment is highly speculative and should not be made by anyone who cannot afford to risk the entire investment amount. In addition to these risks, you should carefully consider the specific information and risks disclosed in Vivid Genomics’s profile.